Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 5, 2003, Pages 376-384

  Pendyala, Lakshmi ^a   Schwartz, Gary ^a,c   Smith, Patrick ^a   Zdanowicz, Joseph ^a   Murphy, Michael ^a   Hausheer, Frederick ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b BioNumerik Pharmaceuticals Inc   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

BNP7787; Cysteine Homocysteine; Disulfides; Glutathione; Thiols

Indexed keywords

CARBOPLATIN; CISPLATIN; CYSTEINE; DIMESNA; DISULFIDE; GLUTATHIONE; HOMOCYSTEINE; IFOSFAMIDE; MESNA; PACLITAXEL; PLATINUM; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER; CANCER CHEMOTHERAPY; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0038695006     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0587-y     Document Type: Article

References (43)

1. Anderson ME (1985) Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113:548
2. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR (1994). Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 12:194
3. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, et al (1987) Characterization of a cis-diamminedichloroplatinum (II) resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414
4. Boven E, Hulscher S, Schluper HM, Erkelens C, van der Vijgh WJ (1998) BNP7787, a new protector against platinum induced toxicities, does not influence the antitumor efficacy of cisplatin or carboplatin. Proc Am Assoc Cancer Res 39:158
5. Burgunder JM, Varriale A, Lauterburg BH (1989) Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 36:127
6. Cavalletti E, Cavaletti G, Tredici G, Oggioni N, Spinelli S, Reddy D, Zhao M, Wu M, Hausheer FH (1999) Oral and intravenous BNP7787 protects against paclitaxel-mediated neurotoxicity in Wistar rats. Proc Am Assoc Cancer Res 40:398
7. Daley-Yates PT, McBrien DCH (1984) Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumor activity of cisplatin. Biochem Pharmacol 33:3063
8. Dechant KL, Brodgen RN, Pilkington T, Faulds D (1991) Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42:428
9. Deleve LD, Kaplowitz N (1991) Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 52:287
10. Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. Am J Physiol 257:L163
11. El-akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L (1996) Altered glutathione metabolism in oxaliplatin resistant A2780 ovarian carcinoma cells. Cancer Lett 105:5
12. El-Yazigin A, Ernst P, Al-Rawithi S, Legayada E, Raines DA (1997) Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation. J Clin Pharmacol 37:618
13. Fahey RC, Newton GL (1987) Determination of low molecular weight thiols using monobromobimane fluorescent labelling and high performance liquid chromatography. Methods Enzymol 143:85
14. Friedman HS, Colvin M, Aisaka K, Popp J, Bossen EH, Reimer KA, Powell JB, Hilton J, Gross SS, Levi R, Bigner DD, Griffith OW (1990) Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res 50:2455
15. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M (1996) Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16:16
16. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC (1993) Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53:5225
17. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM (1998) Modulation of platinum induced toxicities and therapeutic index: mechanistic insights and first and second-generation protecting agents. Semin Oncol 25:584-599
18. Hausheer F, Cavaletti G, Tredici G, Oggioni N, Spinelli S, Pezzoni G, Manzotti C, Haridas K, Reddy D, Zhao M, Seetharamulu P, Yao S, Pavankumar P, Murali D, Wu M, Saxe J, Cavalletti E (1999) Oral and intravenous BNP7787 protects against platinum neurotoxicity without in vitro or in vivo tumor protection. Proc Am Assoc Cancer Res 40:398
19. Hausheer FH, Kochat H, Reddy D, Zhao M, Seetharamulu P, Yao S, Pavankumar P, Murali D, Wu M, Saxe J, Parker A, Hamilton S (2000) BNP7787: a novel chemoprotecting agent for platinum and taxane toxicity. Proc Am Assoc Cancer Res 41:768
20. Hausheer F, Kanter P, Rustum Y, Cao S, Haridas K, Reddy D, Seetharamulu P, Zhao M, Yao S, Pavankumar P, Murali D (2001) BNP7787: a novel antitumor potentiating drug which protects against cisplatin and carboplatin toxicities. Proc Am Assoc Cancer Res 38:311
21. Hausheer FH, Kochat H, Zhao M, Seetharamulu P, Huang Q, Berghorn E (2001) BNP7787, a novel neuroprotective agent in taxane and platinum regimens, does not interfere with antitumor activity. Proc Am Assoc Cancer Res 42:370
22. Kleinman WA, Richie PJ (2000) Status of glutathione and other thiols and disulfides in human plasma. Biochem Pharmacol 60:19-29
23. Lauterburg BH, Nguyen T, Hartmann B, Junker E, Küpfer A, Cerny T (1994) Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 35:132
24. Lowry OH, Rosenbrough MT, Farr AL, Randall RJ (1951) Protein measurement with folin phenol reagent. J Biol Chem 193:265
25. Luo FR, Wyrick SD, Chaney SG (1999) Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 44:19
26. Meister A (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 51:155
27. Mistry P, Harrap KR (1991) Historical aspects of glutathione and cancer chemotherapy. Pharmacol Ther 49:125
28. Mistry P, Loh SY, Kelland LR, Harrap KR (1993) Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Int J Cancer 55:848
29. Muggia FM, Los G (1993) Platinum resistance: laboratory findings and clinical implications. Stem Cells 11:182
30. PDR (2001) Mesnex Injection. Physicians desk reference (PDR electronic library). Medical Economics Company, Montvale, NJ
31. Pendyala L, Creaven PJ (1995) Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev 4:245
32. Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ (1997) Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Cancer Chemother Pharmacol 40:38
33. Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Perez R (2000) Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Clin Cancer Res 6:1314
34. Perez R, Pendyala L, Meropol NJ, Jones V, Kindler H, Loewen G, Schwartz G, Noel D, Proefrock A, Berghorn E, Mahew E, Raghavan D, Creaven PJ (2003) Initial clinical and pharmacokinetic trials of N-phosphonoacetyl-L-aspartate (PALA) plus cisplatin and carboplatin. Cancer (in press)
35. Rocci ML Jr, Jusko WJ (1983) Lagran program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 16:203
36. Schulz JB, Lindenau J, Seyfried J, Dichgans J (2000) Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 267:4904
37. Schwartz GN, Pendyala L, Amantea MA, Humphriss E, Creaven PJ (1998) Pharmacokinetics of platinum (Pt) in a phase I trial of liposomal cisplatin in patients with advanced cancer. Proc Am Assoc Cancer Res 39:364
38. Schwartz GN, Schilsky RL, Pendyala L, Berghorn E, Bertucci D, Ratain MJ, Hausheer FH (2000) Phase I trial of escalating doses of BNP7787 in patients receiving paclitaxel (TAX) and cisplatin (CDDP). Proc ASCO 19:218a
39. Shaw IC, Weeks MS (1987) Excretion of disodium Bis-2 mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol 23:933-935
40. Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54:4313
41. Vanhoefer U, Cao SS, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM (1996) D,L-Buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res 2:1961
42. Verschraagen M, Boven E, Westerman M, Ruijter R, Hausheer FH, Reddy D, Pinedo HM, van der Vijgh WJ (2000) The pharmacokinetic behavior of BNP7787 (dimesna) and its metabolite mesna and the influence of BNP7787 on the pharmacokinetics of (hydrated) cisplatin in cancer patients. Proc Am Assoc Cancer Res 41:606
43. Zaman GJR, Lankelma J, Tellingen OV, Beijnen J, Dekker H, Paulusma C, Oude Elferink RPJ, Bass F, Borst P (1995) Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci U S A 92:7690